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SUMMARY
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the
United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking,
and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced pro-
tection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589
individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike pro-
tein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional
3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior
SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral
responses indicate that extension of the dosing interval is an effective immunogenic protocol.
INTRODUCTION
On December 31, 2020, the United Kingdom Chief Medical Offi-
cers announced changes to the dosing regimen for the second
dose of the Pfizer/BioNTech BNT162b2 and Oxford/AstraZe-
neca severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) vaccines, with the interval between the first and second
dose extended from 3–4 weeks to up to 12 weeks. This policy
was implemented in a bid to avert deaths and prevent hospital-
ization because of severe coronavirus disease 2019 (COVID-19)
and facilitated rapid rollout of one dose of the SARS-CoV-2 vac-
cine, providing a degree of cover as quickly as possible to
prevent disease in a large proportion of higher-risk groups
(Department of Health and Social Care UK, 2021).
The strategy to change regimens was based on estimates of
efficacy after a single dose from clinical trials, modeling, and
data from other vaccines. Although Pfizer’s clinical trial
described an efficacy of 52% against symptomatic infection af-
ter a single dose (Polack et al., 2020), the United Kingdom’s Joint
Committee on Vaccination and Immunisation (JCVI) estimated
an efficacy of 89% against symptomatic infection, having
removed infection data from within the first 14 days following
the first dose (JCVI, 2020). However, this vaccine is based on
novel mRNA technology, and little is known about the durability
of immune responses after a single dose or the effect of extend-
ing dosing intervals.
The success of this strategy depends on the real-world
effectiveness of the single dose of vaccine and on the effect
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of dose intervals on the boost. Viral variants such as delta
(B.1.167.2) may also affect the protective efficacy of the
generated immune responses (Reuters, 2021). We currently
lack clear correlates of protection against SARS-CoV-2,
although recent attempts to compare vaccines have given
some indication of binding and neutralizing antibody measures
that accompany efficacy (Earle et al., 2021; Feng et al., 2021;
Khoury et al., 2021). Importantly, large-scale clinical trial data,
on which these estimates are based, do not include measures
of T cells. Because T cells are of increasing interest for
providing protection (Rydyznski Moderbacher et al., 2020;
Tan et al., 2021), human data to support such a role for cellular
immunity are very valuable.
The United Kingdom SARS-CoV-2 Immunity & Reinfection
Evaluation (SIREN) study is a multicenter prospective cohort
study of staff in National Health Service (NHS) hospitals.
Because of rapid rollout of vaccines to NHS workers in
December 2020 and the high burden of infection with the alpha
variant during the United Kingdom’s second wave, the SIREN
study has emerged as a leading study of the real-world effective-
ness of vaccines for SARS-CoV-2 (Hall et al., 2021). The PITCH
(Protective Immunity from T cells in Healthcare Workers) study
is a multicenter study nested within SIREN, focused on mecha-
nistic studies, including T cell responses, of immunity to SARS-
CoV-2 (Angyal et al., 2021). Samples from the PITCH study
have helped define many features of the serologic response to
variants following natural infection and different vaccine regi-
mens (Dejnirattisai et al., 2021; Liu et al., 2021; Skelly et al.,
2021; Supasa et al., 2021; Zhou et al., 2021) and confirmed
robust immune responses following a single dose of vaccine in
previously infected donors (Angyal et al., 2021). Shortly after initi-
ating the United Kingdom vaccine program, the government
announced a change in protocol for BNT162b2 with a dosing in-
terval of up to 12 weeks. Only a fraction of staff received the con-
ventional (short interval) dosing—the majority received extended
interval dosing.
We aimed to track antibody (Ab) and T cell responses after the
first dose of BNT162b2 mRNA vaccine and compare the magni-
tude of Ab and T cell responses 4 weeks after dose 2 between
short and long vaccination regimens, coupling this with the pro-
tective efficacy data. We observed substantial clinical protection
in the face of the alpha variant, accompanied by rapid induction
of humoral and cellular immune responses, including neutralizing
Abs (NAbs), mostmarked in thosewith a history of prior infection.
Extension of the interval led to a higher level of NAbs following
the second dose. These data define the effects of dose exten-
sion and offer immunological support for decision-making
regarding vaccine dosing intervals.
RESULTS
Protection induced by BNT162b2 using an extended
dosing interval
To demonstrate the effect of extended dosing intervals on vac-
cine effectiveness against infection, we analyzed data from the
entire SIREN study cohort. This study undertook clinical follow-
up of 25,066 healthcare workers (HCWs) between December 7,
2020 and March 12, 2021 with asymptomatic screening by
PCR over a period of up to 95 days (13.6 weeks) from the first
dose of BNT162b2. At this time, the alpha (B.1.1.7) variant was
the dominant circulating virus in the United Kingdom. These
data are derived from prospective follow-up of the cohort
(Hall et al., 2021). The time-resolved data show a gradual in-
crease in the estimate of protection against all infections
(asymptomatic and symptomatic) afforded by the vaccine
following the first dose in individuals who were seronegative
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prior to vaccination (Figure 1A). A hazard ratio for infection of
less than 50% is reached after about 14 days, with protection
maintained at high levels until the second dose and then until
the end of the follow-up period (although with wide confidence
intervals because of decreasing numbers). The hazard ratios
are adjusted (including for age, ethnicity, comorbidities, and re-
gion), and the lower hazard ratio seen on days 0–3 is explained
by deferral of vaccination in symptomatic individuals. Overall,
these data show robust protection against infection following
A
B
Figure 1. Vaccine efficacy and study design
(A) Adjusted hazard ratios with 95% confidence
intervals for PCR confirmed cases by interval after
first and second doses of vaccination (source: SI-
REN study). HCWs underwent regular asymp-
tomatic PCR screening (n = 25,066; negative
cohort, 16,423; positive cohort, 8,643) with follow-
up to 95 days after the first dose of the BNT162b2
vaccine. The hazard ratios are adjusted (including
for age, ethnicity, comorbidities, and region), with
full methodology described (Hall et al., 2021).
(B) Schematic showing the dosing strategies of
short and long vaccine intervals and phlebotomy
time points.
the first dose of BNT162b2, with vaccine
effectiveness reaching 72% by 3 weeks
after dose 1 and maintained following
the boosting second dose.
Participants of the PITCH study
589 participants received two doses of
the BNT162b2 Pfizer/BioNTech vaccine
between December 9, 2020 and May
23, 2021 in 5 United Kingdom NHS hos-
pital centers, with the majority undergo-
ing the extended dosing schedule. The
median age was 43 years (interquartile
range [IQR], 32–52; range, 21–71) with
74% (431 of 582 reported) females, re-
flecting the demographics of the parent
SIREN study (Hall et al., 2021), and
15% (72 of 482 reported) from an ethnic
minority group (Table 1). Individuals were
defined as SARS-CoV-2 naive (334,
57%) or previously infected (255, 43%)
based on documented PCR and/or
serology results from local NHS trusts
or the mesoscale discovery (MSD) assay
spike (S) and nucleocapsid (N) Ab re-
sults. In those infected previously, 59%
(150 of 255) had a SARS-CoV-2-positive
PCR test result a median of 8.7 (IQR,
7.5–9.3) months prior to vaccination.
The vaccine dosing interval was the
conventional ‘‘short’’ 2- to 5-week interval
(n = 86; median, 24 days; IQR, 21–27;
range, 14–35) or a ‘‘long’’ 6- to 14-week
interval (n = 503; median, 71 days; IQR,
64–77; range, 45–105) (Figure 1B; Table 1). An overview of the
assays is shown in Table S1.
Priming and boosting of serologic responses to SARS-
CoV-2 using the extended dosing schedule
We next explored the immune responses accompanying this pro-
tection in the inter-dose interval. First, usingSARS-CoV-2-naive in-
dividuals in the smaller immunology cohort (PITCH study), NAb
levels were tested using a live virus microneutralization assay, as
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reported previously (Dejnirattisai et al., 2021; Liu et al., 2021; Su-
pasa et al., 2021; Zhou et al., 2021).MeasurableNAb titers against
the early pandemic virus (Victoria) were observed in themajority of
participants tested 4 weeks after the first dose (all infection naive),
with a median 50% focus reduction neutralization titer (FRNT50) of
around 102 at this time point (Figure 2A). For the tested variant vi-
ruses—beta (B.1.351), gamma (P.1), and delta (B.1.167.2)—there
was very limited detection of NAbs against beta and delta after
one dose but only a minimal reduction in titers against gamma
compared with Victoria. Although the alpha variant was not as-
sayed in this set of experiments, extensive previous comparisons
have indicated a consistent drop in titer of around 3-fold (Supasa
et al., 2021). These titers declined up to 3-fold following the peak
and were boosted markedly following the second dose.
Using a multiplex ELISA (MSD) to measure anti-S Abs, we
saw a similar pattern of decline following the first vaccine
dose and boosting following the second dose in naive partic-
ipants (Figure 2B). A parallel phenomenon was seen in the
previously infected group; the levels of anti-S Ab prior to the
first dose were present at a level approaching that seen after
a single dose in the naive group and boosted substantially by
the first dose. Overall, neutralization levels correlated with S
and receptor binding domain (RBD) binding titers (Figures
S1A–S1D). Linear mixed-effects regression models were
used to confirm these findings after adjusting for age and
sex (Table 2).
In summary, a clear humoral response against the vaccine
strain virus is induced by a single dose of vaccine across the
cohort, although with NAbs at relatively low levels, especially
against the beta variant and delta variants. The peak NAb
response following priming is followed by a decline during the
extended dose interval, most marked in naive individuals, with
a boost after the second dose.
Induction and maintenance of anti-S T cell responses
using the extended dosing schedule
We next investigated the T cell response using an established
interferon-gamma (IFNg) enzyme-linked immune absorbent
spot (ELISpot) assay (Angyal et al., 2021; Ogbe et al., 2021).
The S-specific T cell response was well maintained during the
10 weeks following the primary vaccine, with no evidence of
contraction, a phenomenon that was seen equally in the previ-
ously infected and naive groups (Figure 2C). T cells were boosted
by the second dose in both groups, with the greatest effect seen
in the naive group. In contrast, responses to the non-S T cell tar-
gets (membrane [M] and N) showed only minimal changes over
this period in both groups (Figure 2C). Linear mixed-effects
regression models were again performed to confirm these re-
sults after adjusting for age and sex (Table 2).
These data demonstrate maintenance of cellular responses
using the extended dosing approach. We did not see a signifi-
cant relationship between NAbs and the T cell response to S
(Figures S1E–S1H).
Extension of the dosing interval leads to an increase in
peak NAbs and B cells but not T cells
Wenext compared immune responses in the SARS-CoV-2-naive
cohort vaccinated using the longer dosing interval with those
vaccinated using the conventional 3- to 4-week (short) interval.
We noted higher NAb titers (4 weeks after the second dose of
both regimens, all infection naive) in individuals vaccinated using
the long interval regimen, with a 2- to 4-fold increase in titer, de-
pending on the variant tested (Figure 3A), with a correlation
across time (Figure S1I). In each case, titers against the Victoria
(B) virus were greater than against the tested beta, gamma, and
delta variants, with the greatest reduction in titer noted against
the beta variant, where the benefit of the longer dosing interval
was also greatest. These data were confirmed using a secondary
assay based on RBD binding inhibition to ACE2 (MSD) (Fig-
ure 3B). Again, a clear increase is seen with extended dosing
across the tested variants (including the alpha variant, which
was circulating widely during the period of this study), and this
was most evident in the infection-naive cohort.
We also tested the effect of the dosing interval on binding
Abs using S, RBD, and N as targets, splitting the cohort by pre-
vious exposure. A clear advantage of the longer interval was
seen again, although only in the naive cohort (Figure 3C). The
previously infected cohort had equally high levels of binding
to S and RBD regardless of vaccine regimen (Figure 3C).
Generalized linear regression models were performed to
confirm these findings after adjustment for age, sex, and previ-
ous infection status, with separate models run for naive and








Median days 70 23.5 71
Median weeks 10.00 3.36 10.14
IQR (days) 63–77 21–27 64–77
Range (days) 14–105 14–35 45–105
N 589 86 503
Female, n (%) 431 (74%) 45 (56%) 386 (77%)
Male, n (%) 151 (26%) 36 (44%) 115 (23%)
Sex unreported, n 7 5 2
Mean age 42.30 44.96 41.87
Age in years,
median (IQR)
43 (32–52) 45 (37–54) 43 (31–51)
Age range 21–71 22–64 21–71
Infection status
Naive, N (%) 334 (57%) 57 (66%) 277 (55%)
Previous
SARS-CoV-2, N (%)
255 (43%) 29 (34%) 226 (45%)
Ethnicity (self reported)
White, n (%)a 410 (85.1%) 58 (84%) 352 (85%)
Asian, n (%)a 45 (9.3%) 7 (10%) 38 (9%)
Black, n (%)a 7 (1.5%) 0 (0%) 7 (2%)
Other, n (%)a 20 (4.1%) 4 (6%) 16 (4%)
Unreported, n 107 17 90
IQR, interquartile range.
aPercentage of reported ethnicities.
ll
OPEN ACCESS















































































































































NS P = 0.0002
2.95





































































P < 0.0001 P < 0.0001
7.46















































































(legend on next page)
ll
OPEN ACCESS
Cell 184, 5699–5714, November 11, 2021 5703
Article
previously infected individuals (Table 3). No effect of ethnicity
was seen in a reduced dataset (n = 143) where this information
was available (Table S2).
Comparing anti-S responses with dosing interval grouped
around 4-, 6-, 8-, 10-, and 12-week intervals, we saw a signifi-
cant difference for infection-naive HCWs between dose intervals
of 4 versus 10 or 12weeks but no significant differences between
other intervals, such as 8 weeks versus 12 weeks, and no differ-
ence for previously infected HCWs (Figure S2A). A number of in-
dividuals defined previously as naive at baseline on the basis of
serology and infection history (14 of 138, 10.1%) showed reac-
tivity to N in this MSD immunoglobulin G (IgG) assay 4 weeks af-
ter the second dose, suggesting infection/exposure during the
period of observation. We tested whether removing these indi-
viduals in the naive group who seroconvert to anti-N affected
the result (Figure S2B) and found that the higher binding Ab re-
sponses to S and RBD remained significant.
SARS-CoV-2 S-specific B cell responses showed induction
and maintenance during the extended interval between the first
and second dose in infection-naive participants (Figure 3D), and,
indeed, the magnitude of the antigen-specific B cell response
10 weeks after one dose in the extended interval cohort was
higher than 4 weeks after one dose in the short interval cohort,
supporting continued B cell development beyond 4 weeks after
a prime. 4 weeks after the second dose, we saw a nearly 7-fold
increase in themagnitude of the B cell response for the extended
interval cohort compared with the short interval, in parallel to the
higher Abs seen.
Extension of the dosing interval did not lead to greater induc-
tion of T cell responses following the second dose (Figure 3E).
Indeed, although for those infected previously there was no dif-
ference detected, for those previously naive we found a
modestly lower T cell response weeks after the longer dosing in-
terval compared with the shorter interval. Responses to control
antigens (CEF - cytomegalovirus, Epstein-Barr virus, and influ-
enza) were unaffected by prior exposure or regimen, whereas re-
sponses to SARS-CoV-2 M and N proteins were, as expected,
associated with prior exposure but stable over time. There was
a weak correlation between binding Abs and T cell response
4 weeks after the second dose, with no obvious effect of re-
ported ethnicity (Figure S3A) although the study was underpow-
ered for full evaluation of ethnicity. Generalized linear regression
models were performed to confirm these findings after adjust-
ment for age, sex, and previous infection status (Table 3). No ef-
fect of ethnicity was seen in a reduced dataset where this infor-
mation was available (n = 277; Table S2).
We next compared the functionality of these T cell responses
4 weeks after the second dose in more depth in 86 HCWs using
intracellular cytokine staining (ICS). For this analysis, we
selected only participants with positive ELISpot assays, which
we defined as > 40 spot-forming units per million peripheral
bloodmononuclear cells (PBMCs), themean of the DMSO nega-
tive values + 2 standard deviations, because, in previous studies
(Angyal et al., 2021; Ogbe et al., 2021), we observed that the
smaller frequency populations are hard to detect by flow cytom-
etry and also prone to inaccuracy because of low cell numbers.
We sawmarked skewing in the CD3+ T cell compartment toward
a S-specific CD4+ T cell response with the long dosing interval
but more balance between CD4+ and CD8+ for the short interval
(Figure 4A; representative gating strategy in Figure S4). Further
analysis showed that, within the CD4+ compartment, S-specific
responses for all cytokines tested were higher in naive partici-
pants using the long dosing interval compared with the short in-
terval, whereas no differences were observed in the previously
infected participants (Figure 4B). In contrast, within the CD8+
compartment, there were no differences in S-specific responses
except for CD8+ IFNg responses, which were lower in partici-
pants on the long dosing interval, irrespective of pre-infection
status (Figure 4C).
These experiments revealed that infection-naive recipients of
the long dosing interval generated a higher interleukin-2 (IL-2)
CD4+ response to S compared with the short dosing interval,
along with higher IFNg and tumor necrosis factor (TNF) CD4+ re-
sponses (Figure 4B), whereas the CD8+ response was reversed,
with lower IFNg responses for the long interval (Figure 4C).
By comparing the proportions of polyfunctional CD4+ T cells
between the long and short dosing groups, we observed an
increased CD4+ T cell polyfunctionality in naive participants
who had undergone the extended dosing interval compared
with the short dosing interval (Figure 4D). No difference in poly-
functionality was observed in previously infected participants.
The comparison of CD8+ T cell polyfunctionality was limited by
Figure 2. The long dosing interval with the BNT162b2 (Pfizer-BioNTech) vaccine elicits distinct NAb titer profiles against SARS-CoV-2
variants of concern and maintains T cell responses
(A) NAbs against the Victoria isolate, B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta) taken from naive participants 4 (n = 20) and 10weeks (n = 20) after the first
vaccine dose and 4 weeks (n = 20) after the second vaccine dose in the long interval cohort. x axis, weeks since dose. Geometric mean neutralizing titers are
shown immediately above each column and marked by a horizontal line on each column with 95% confience intervals. FRNT, focus reduction neutralization
assay; FRNT50, the reciprocal dilution of the concentration of serum required to produce a 50% reduction in infectious focus-forming units of virus in Vero cells
(ATCC, CCL-81).
(B) SARS-CoV-2 spike (S)-, receptor binding domain (RBD)-, and nucleocapsid (N)-specific IgG time course using multiplexed MSD immunoassays in 29 naive
and 29 pre-infected individuals vaccinated with a long interval between the doses. Data are shown in arbitrary units (AU)/mL. Horizontal dotted lines represent the
cutoff of each assay based on pre-pandemic sera.
(C) Comparison of IFNg ELISpot responses to S (Victoria) from cryopreserved peripheral blood mononuclear cells (PBMCs) in 26 naive individuals and 26
previously infected individuals with a long interval between doses. Data are shown in spot-forming units per million PBMCs (SFU/106).
Gray circles, naive individuals; red circles, previously infected individuals. Pre, before vaccine; 1-dose + 4 weeks, 4 weeks after the first dose; 1-dose + 10weeks,
8–12 weeks after the first dose; 2-dose + 4 weeks, 4 weeks after the second dose. Bars for (B) and (C) represent the median with interquartile range. Time points
for (A) were comparedwith Kruskal-Wallis nonparametric test and Dunn’smultiple comparisons tests, with p values shown above linking lines and fold changes in
brackets. Paired comparisons were performed for (B) and (C) using the Wilcoxon matched pairs signed rank test, with fold change values referring to the p value
comparisons directly below. Data in (B) from 51 of the pre-vaccine and 51 of the 1-dose + 4 weeks responses as well as data from (C) from 51 of the pre-vaccine
and 51 of the 1-dose + 4 weeks responses have been published previously (Angyal et al., 2021).
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Table 2. Linear mixed-effects regression models of T cell (IFNg) or Ab (IgG) immune responses
S T cell responses in
naive participants
S T cell responses in
pre inf participants
S Ab responses in
naive participants
S Ab responses in
pre inf participants
Coefficient Estimates CI (95%) p Value Estimates CI (95%) p Value Estimates CI (95%) p Value Estimates CI (95%) p Value
Intercept 1.47 0.95–1.98 <0.001a 1.92 1.26–2.59 <0.001a 4.84 4.42–5.26 <0.001a 5.77 5.41–6.12 <0.001a
Age 0.00 0.02 to 0.01 0.705 0.01 0.01 to 0.02 0.480 0.01 0.02 to 0.00 0.090 0.00 0.01 to 0.01 0.640





<0.001a 0.88 1.09 to
0.67
<0.001a 2.79 2.95 to
2.63




1 + 10 weeks)
0.28 0.01 to 0.57 0.060 0.08 0.13 to 0.28 0.466 0.38 0.53 to 0.22 < 0.001a 0.18 0.29 to 0.07 0.002a
Time point (dose
2 + 4 weeks)
0.85 0.56–1.13 <0.001a 0.31 0.10–0.51 0.003a 0.97 0.81–1.12 <0.001a 0.02 0.13 to 0.10 0.793
Random effects
s
2 0.28 0.14 0.09 0.05
t00 0.06 PubID 0.12 PubID 0.09 PubID 0.04 PubID
ICC 0.18 0.46 0.49 0.43
N 26 PubID 26 PubID 29 PubID 29 PubID
Observations 103 104 116 116
Marginal
R2/conditional R2
0.506/0.593 0.462/0.710 0.914/0.956 0.848/0.913
Shown are four linear mixed-effect regression models (LMERs) of T cell or Ab responses in naive or pre-inf individuals across vaccine time points in the long vaccine dose regimen. Variables
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B.1.351/beta P.1/gamma B.1.617.2/delta
P < 0.001(3.9X) P < 0.001(1.9X) P = 0.002(2.3X)
Naive participants


















Short Long Short Long Short Long Short Long
B1.1.7/alpha B1.351/beta P.1/gamma
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Fold Change
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Figure 3. Comparison of IgG responses and T cell responses 4 weeks after the second dose of vaccine
(A) Comparison of NAbs against the Victoria isolate, B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta) 4 weeks after the second dose with short (n = 19) and long
(n = 20) interval in naive participants. There is amedian of 3.3 weeks (range, 2.4–4.3) between doses in the short interval cohort and 8.4 weeks (range 6.4-10) in the
(legend continued on next page)
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the small number of HCWs who showed CD8+ responses suffi-
cient for this analysis but did not suggest any large differences
between the groups.
The combined ELISpot and ICS data show a modest differ-
ence in T cell responses between long and short regimens,
with both regimens inducing and maintaining robust CD4+ and
CD8+ responses in naive and previously infected donors. The
longer dosing interval was linked to induction of higher levels
of IL-2-secreting CD4+ T cells in the naive group, accompanied
by slightly lower levels of IFNg-secreting CD8+ T cells.
Comparison of naive and previously infected individuals
Throughout the analyses, we noted differences in responses be-
tween naive and previously infected individuals. To explore this
further, we used a larger dataset of all available unpaired data
across the time course (n = 589 participants) and performed a
side-by-side analysis of humoral and cellular responses
following first and second dose, including 13 weeks (3 months)
after the second dose where samples were available (Figures
S5A–S5D). 4 weeks after a single dose of vaccination, previous
infection gives a significant advantage in the magnitude of anti-
S IgG Abs (approximately 8–fold; Figure S5A) and of T cell
response (approximately 5-fold; Figure S5C) (as reported in
Angyal et al., 2021). 4 weeks after 2 doses, there is still a statis-
tically significant difference in Ab and T cell response between
those with and without previous infection, although the magni-
tude is less pronounced (up to 3-fold). In those with previous
infection, there was consistent evidence of higher neutralization
activity against variants of concern using the RBD binding inhibi-
tion to ACE2 assay (Figure S5D), suggesting that ‘‘hybrid immu-
nity’’ from previous infection plus vaccination gives the strongest
cross-reactive neutralization.
We recently identified an association between the interval
separating prior infection until the first dose and the magnitude
of Ab response to the first dose in previously infected individuals.
This association shows that a longer interval is associated with a
stronger IgG response to first dose of the vaccine (Angyal et al.,
2021). Our finding that higher IgG levels are associated with
longer dosing intervals in naive individuals provides parallel evi-
dence that longer intervals between antigen exposure favors in-
duction of higher Ab levels.
Two doses of BNT162b2 induced Ab against the S protein of
other betacoronaviruses, with novel induction of IgG against se-
vere acute respiratory syndrome (SARS) and Middle East respi-
ratory syndrome (MERS) viruses (Figure S3C) and boosting of
baseline IgG against the human seasonal betacoronaviruses
HKU1 and OC43. There was no significant boosting of baseline
Abs against the human seasonal alphacoronaviruses NL63
and 229E.
Dynamics of immune responses following boosting
We next addressed the dynamics of immune responses
following a second dose boost. Tracking NAb responses
following the short regimen, we found a peak 1 week after the
second dose, with a subsequent clear decline in circulating
NAb titers against Victoria and variant viruses over the subse-
quent time points (4 weeks and 13 weeks after the second
dose, all infection naive; Figure 5A). The decline against the Vic-
toria strain between weeks 1 and 4 is approximately 4-fold,
which compares with around 3-fold between weeks 4 and 13
and, thus, around 12-fold over the overall 3-month period. Future
studies will evaluate the durability of the extended dosing
interval.
We observed maintenance of T cell responses over the same
period (Figure 5B). These responses showed a very modest but
statistically significant loss of activity against peptide pools from
the variant S protein sequences—namely, the beta (1.18-fold
lower, p = 0.0001) and gamma (1.1-fold lower, p = 0.0016) vari-
ants compared with the wild-type sequence—but no loss of ac-
tivity against the delta variant (fold change = 1.00, p = 0.2058)
Figure 5C).
These data recapitulate the data seen after a single dose. That
is, there is a clear decline in circulating Abs over a 3-month
period, with strong maintenance of the T cell response. This is
a period well studied in clinical trials, where robust protection
following a second dose was observed (Polack et al., 2020).
DISCUSSION
Extended dose intervals for boosting COVID-19 mRNA vaccines
were introduced based on an interpretation of clinical trial data
for BNT162b2 and extrapolation from the AstraZeneca vaccine
long interval cohort. Geometric mean neutralizing titers with 95% confidence intervals are shown. FRNT, focus reduction neutralization assay; FRNT50, the
reciprocal dilution of the concentration of serum required to produce a 50% reduction in infectious focus-forming units of virus in Vero cells (ATCC, CCL-81).
(B) Effect of a short and a long vaccine dosing interval on the ability of sera to inhibit ACE2 binding to SARS-CoV-2 S (Victoria, B.1.1.7 [alpha], B.1.351 [beta], or P.1
[gamma]) 4 weeks after the second dose. ACE2 inhibition was analyzed using a multiplexed MSD assay. Data are shown in units/mL. Bars represent the median
with 95% confidence intervals. Naive, short: n = 23; naive, long: n = 94; previously infected (pre inf), short: n = 14; pre inf, long: n = 119.
(C) Effect of a short or a long vaccine dosing interval on SARS-CoV-2 S-, RBD-, and N-specific IgG responses in naive (gray circles) and pre individuals (red
circles). IgG responses were measured in serum 4 weeks after the second dose using multiplexed MSD immunoassays and are shown in arbitrary units (AU)/mL.
Naive, short: n = 41; naive, long: n = 151; pre inf, short: n = 19; pre inf, long: n = 169. Horizontal dotted lines represent the cutoff of each assay based on pre-
pandemic sera.
(D) IgG B ELISpot responses from cryopreserved peripheral blood mononuclear cells (PBMCs) 4 weeks after the first dose in naive short (n = 9), 2 weeks after the
second dose in naive short (n = 12), 10 weeks after the first dose in naive long (n = 10), and 2 weeks after the second dose in naive long (n = 10). Values are
expressed as spot-forming units per million PBMCs (SFU/106) representing anti-S IgG-secreting cells.
(E) IFNg ELISpot responses from cryopreserved PBMCs 4weeks after the second dose in naive short (n = 37), naive long (n = 188), pre inf short (n = 20), and pre inf
long (n = 124) individuals. Values are expressed as SFU/106. Displayed are responses to peptide pools representing S1 and S2 subunits of S (Victoria), peptide
pools representing membrane (M) and N proteins (N) and cytomegalovirus, Epstein-Barr virus, influenza, and tetanus antigens (CEF).
Bars represent the median with interquartile range for (B), (C), (D), and (E). Time points were compared with two-tailed Mann-Whitney tests, with p values shown
above linking lines and fold changes in brackets for (A) and fold change values referring to the p value comparisons directly below for (B)–(E).
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and vaccines for other pathogens but without a strong dataset
for BNT162b2 to support the immunology or real-world clinical
effectiveness. Here we provide an extensive serological and
T cell assay dataset to explore the vaccine effectiveness seen
in the parent SIREN study. The serologic response to one or
two doses of BNT162b2 falls over time and is higher after an
extended dosing interval in infection-naive participants
compared with the 3- to 4-week dosing interval that was tested
in the licensing trials. As reported previously (Dan et al., 2021;
Goel et al., 2021; Turner et al., 2021), we found S-specific
B cell responses to be well maintained in contrast to the Ab re-
sponses, and we found them to be around 7-fold higher in the
infection-naive extended dosing interval cohort. The T cell
response is well maintained after one and two doses. The sus-
tained T cell response from 1 to 10 weeks after the first dose in
the extended dosing interval group contrasts with the waning
of T cells we and others (Dan et al., 2021; Tomic et al., 2021)
have reported after natural infection. In addition, maintenance
of T cell responses from 1 to 13 weeks after the second dose
contrasts with some other longitudinal vaccine studies where
T cell responses peaked 1 week after boost (Esposito et al.,
2020; Swadling et al., 2014; Venkatraman et al., 2019). The
T cell response is of a marginally lower magnitude after the
longer dosing interval when measured by the ELISpot assay of
T cell effector function, with higher IL-2, IFNg, and TNF CD4+
responses and lower IFNg CD8+ responses compared with the
3- to 4-week dosing interval. Ongoing work when this cohort rea-
ches 6 months after the second dose will evaluate whether the
variation in T cell functionality 4 weeks after the second dose
translates into differences in sustained memory.
The data from the larger clinical study in SIREN provide clear
evidence of a protective effect of a single dose against the circu-
lating alpha variant over an extended period. The SIREN study is
based on prospective screening for infection rather than reactive
testing based on symptoms alone and therefore provides a
robust measurement of protection. The number of unvaccinated
individuals dropped over the period of study, leading to a wide
confidence interval for the estimates of efficacy, but there is no
evidence of a decline over the first 3 months and, if anything, a
trend to increasing protection, which is sustained following
the boost.
Protection over this extended interval between doses and,
indeed, after the boost may be provided by a range of mediators,
including circulating NAbs and effector T cells as we have
measured, but also many factors beyond peripheral blood that
we have not measured. There is likely to be a strong component
of protection mediated by mucosal immune responses,
including local IgA and IgG (Fröberg and Diavatopoulos, 2021),
as well as resident memory T cells in the respiratory tract (Niessl
et al., 2021), which requires further investigation in future.
Several studies have demonstrated functional Ab responses
beyond neutralizing function against SARS-CoV-2 after infection
and vaccination (Barrett et al., 2021; Bartsch et al., 2021; Tomic
et al., 2021). Other interesting observations that support a role of
T cells in protection come from analyses in the setting of the beta
variant outbreak in South Africa (Moore et al., 2021). T cell re-
sponses are not substantially affected overall by the emerging











































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Analysis of S-specific T cell responses by flow cytometry
Cryopreserved PBMCs from 86 participants who received the short or long vaccine dosing interval, with S antigen-specific ELISpot responses over 40 SFU/
million PBMCs 4 weeks after the second dose, were analyzed by ICS and flow cytometry.
(A) The T cell populations responsible for IFNg or IL-2 expression were assessed by reporting the ratio of IFNg- or IL-2-expressing cells among CD4+ or CD8+
cells, expressed as a proportion of their CD3+ live population.
(legend continued on next page)
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in particular with the beta variant. The protective efficacy of vac-
cines such as Ad26 in South African trials has therefore been hy-
pothesized to link to cellular immunity. Other data that have
explored the relative role of Ab and T cells in protection come
from more mechanistic animal studies, where depletion of
CD8+ T cells in SARS-CoV-2 convalescent macaques affected
protective natural immunity against re-challenge when Ab levels
were waning (McMahan et al., 2021).
The most significant observation of this study is that boosting
after a longer interval leads tomaintained immunogenicity. There
is a distinct effect on anti-S responses, with an increase in NAbs,
as seen for longer dosing intervals with the AstraZeneca 1222
vaccine (Voysey et al., 2021), but a modest reduction in the
IFNg-producing ELISpot response compared with conventional
(short) interval dosing. Although the difference in T cell response
is quite small, it is reproducible with different assays andwas also
seen in a study of an elderly United Kingdom cohort (Parry et al.,
2021). The short and long dosing regimens result in induction of
substantial T cell responses. The short dosing interval gives a
slightly higher IFNg-producing T cell response, consistent with
effector functions, with CD4+ and CD8+ contributions, whereas
the longer dosing interval results in aCD4+dominated phenotype
with marked IL-2 production to S. A study from Public Health En-
gland (PHE) hasconfirmedhigherAb levels after extendeddosing
intervals compared with short ones and has provided the first ev-
idence of high vaccine effectiveness for extended dosing interval
(Amirthalingam et al., 2021). As the authors discuss, some resid-
ual confounding between groups is likely to remain, and further
studies will follow. There is currently no agreed correlate of pro-
tection, but it has been suggested that, in a study of AZD122,
an average level of 40,923 arbitrary units (a.u.)/mL 4 weeks after
the second dose for anti-S IgG using the MSD assay used in this
study, equivalent to 264 binding Ab units (BAUs)/mL using the
WorldHealthOrganization (WHO) international standard, is asso-
ciated with 80% protection from symptomatic infection for the
population of recipients receiving that vaccine regimen (Feng
et al., 2021). However, this was predominantly against the alpha
variant. The average levels for all groups in our study exceeded
this threshold, in line with other studies reporting higher Ab levels
after double vaccination with BNT162b2 compared with AZD122
(Liu et al., 2021).
The CD4+ helper T cell response induced by the extended
dosing interval gives potential mechanistic insight into the
increased Ab boost because IL-2 provides important help for
B cells to develop into plasmablasts (Hipp et al., 2017; Le Gallou
et al., 2012). Benefits of longer intervals between vaccine doses
have been observed for other vaccines in mouse and human
studies, where early boosting results in higher numbers of termi-
nally differentiated and effector T cells, whereas later boosting
promotes efficient T cell expansion and enhanced long-term
memory cell persistence (Capone et al., 2020; Steffensen
et al., 2013). Therefore, a longer interval between vaccine doses
in infection-naive people may allow S-specific T cells to fully
differentiate into memory T cells that respond optimally to S re-
exposure. Interestingly, extension of the interval between prior
infection and prime in a group with previous exposure also leads
to enhanced humoral immunity (Angyal et al., 2021). Because the
first vaccine in previously infected individuals is effectively a
boost for the memory pools concerned, this is consistent with
the current study’s observation of higher humoral immunity for
extended dosing interval recipients in the naive group and the
observation that there is much less of an effect of dosing interval
for the previously infected group.
Our study builds on findings from studies showing that, after a
single vaccine dose, previous infection primes for higher Ab and
T cell responses after vaccination (Angyal et al., 2021; Bradley
et al., 2021; Ebinger et al., 2021; Manisty et al., 2021). After
two doses of vaccine, previous infection continues to give an
advantage in terms of the measured Ab and T cell response
and cross-neutralization to variants of concern, albeit with a
less marked difference in magnitude compared with after a sin-
gle dose. The functional importance of this in terms of protection
and effect on durability of the responses remain to be elucidated.
Past infection may confer other advantages, including mucosal
immunity, Ab and T cell responses to other viral antigens beyond
S, and differences in the character of the response.
Regardless of the dosing regimen, there remains a large
amount of inter-individual variability in the vaccine responsive-
ness for humoral and cellular responses. Overall, we see a corre-
lation between the two measures when responses across all
time points are considered, but there was no relationship be-
tween NAb and T cell responses (ELISpot) when the time point
4 weeks after the second dose was considered alone. The effect
of the dosing interval and the effect of boosting on individuals
with prior infection was much less evident than in naive individ-
uals. We also examined the influence of age, sex, and ethnicity
in our cohort. Although these observations are limited by the
numbers studied and balance of the cohort, we did not observe
any substantial effect in simple comparative or multivariate ana-
lyses except for a modest effect of older age associated with
lower Ab levels in naive HCWs. It remains likely, however, that
genetic effects, such as human leukocyte antigen (HLA) type,
do play a role because this has been shown in other vaccine set-
tings (Mentzer et al., 2015), and the effect of exposure to other
betacoronaviruses remains to be explored further.
The immunogenicity of longer regimens appears to be robust
and, for Abmeasurements, improved over the conventional 3- to
4-week regimen. We provide evidence that T cells are induced
and sustained during the longer period between doses in the
6- to 14-week regimen, but there is an effect of dosing interval
(B and C) The individual cytokine expression levels of total IFNg, IL-2, or TNF are reported as a proportion of the (B) CD4+ T cell population or (C) CD8+ T cells with
addition of CD107a (a marker of cytotoxicity).
(D) Polyfunctionality was evaluated by expression of one or more cytokines in CD4+ cells, showing the number of cytokines released in each group and against
each IFNg, IL-2, and/or TNF gated combination shown as a proportion of total CD4+ T cells.
Naive short, n = 23; naive long, n = 30; pre inf short, n = 14; pre inf long, n = 19. Bars represent the median with interquartile range. Unpaired comparisons across
two groups were performed using Mann-Whitney test, and paired comparisons were performed using Wilcoxon matched pairs signed rank test. Grey circles,
naive individuals; red circles, pre inf individuals.
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Figure 5. Short dosing interval with the BNT162b2 (Pfizer-BioNTech) vaccine elicits distinct NAb titer profiles against SARS-CoV-2 variants
of concern that decline over time, whereas T cell responses are maintained
(A) NAb titers, measured by FRNT, against the early pandemic Victoria isolate, B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta) from naive participants in weeks
1 (n = 25), 4 (n = 19), and 13 (n = 20) after the second vaccine in the short interval dose cohort (median dose interval, 3.3 weeks; range, 2.4–4.3). The x axis indicates
weeks since dose. Geometric mean neutralizing titers with 95% confidence intervals are shown. Neutralization titers from dose 2 + 1 week (Victoria, B.1.351, P.1,
and B.1.617.2) and dose 1 + 4 weeks and 10weeks (Victoria and B.1.617.2) have been reported previously (Dejnirattisai et al., 2021; Liu et al., 2021; Supasa et al.,
2021; Zhou et al., 2021).
(B) Comparison of IFNg ELISpot responses to S Victoria from cryopreserved PBMCs in 43 naive individuals and 26 pre inf individuals who received the short
interval dose 1, 4, and 13 weeks after the second dose.
(C) Comparison of IFNg ELISpot responses from cryopreserved peripheral blood mononucelar cells (PBMCs) in 40 naive individuals and 42 pre inf individuals
matched for responses to S Victoria, spike B.1.35/beta, and S P.1/gamma. Individuals received the long interval dosing regimen, and samples were taken
4 weeks after the second dose. Data are shown as spot forming units (SFU) per million PBMCs.
Time points for (A) were compared with Kruskal-Wallis non-parametric test and Dunn’smultiple comparisons tests. The p values are illustrated above linking lines
and fold changes in brackets. Bars represent the median with interquartile range for (B) and (C). Time points were compared with two-tailed Mann-Whitney tests
for (A) and (B), and paired comparisons were performed using Wilcoxon matched pairs signed rank test for (C), with fold change values referring to the p value
comparisons directly below. Gray circles, naive individuals; red circles, pre inf individuals.
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on the relative proportion of T cell subsets. Ongoing studies in
this cohort will monitor the durability of Ab and T cell responses
6 months after a second 2nd vaccine dose delivered in an
extended dosing interval and response to third ‘‘booster’’ doses
where given. For policy makers, optimal dosing intervals may
depend on community prevalence, population immunity from
natural infection, circulating variants of concern, and vaccine
supply. A short dosing interval gives early protection, whereas
an increased interval appears to improve peak NAb levels.
Limitations of the study
This study provides detailed information at relative scale about
the immune response to the BNT162b2 vaccine in a healthy,
working-age population to help us understand vaccine effective-
ness against the alpha variant seen in the SIREN study and in the
United Kingdom as a whole. The limitations of this study include
first of all the predominance of females and white ethnicity,
reflective of the HCWs we were able to recruit, although neither
female sex nor ethnicity were revealed as significant variables in
our modeling analysis. Second, laboratory measurements such
as low NAb levels are subject to threshold effects and may not
reflect true functional immunity upon re-exposure to the S pro-
tein. Third, ongoing follow-up to evaluate the effect of dosing in-
terval on the durability of the immune response is needed.
Fourth, the high heterogeneity of Ab and T cell responses we
observed means that our findings of higher levels of Abs and
T cell memory function after an extended dosing interval are of
most relevance at a population level rather than at an individual
level. Fifth, although we know the vaccine effectiveness in the
parent cohort (SIREN), we did not measure this directly in the
same individuals in whomwemade T cell and Abmeasurements,
meaning that we cannot directly measure novel correlates of
protection in this study. Finally, the group sizes were skewed to-
ward a much bigger number of participants in the long interval
schedule because the sudden change in policy during the rollout,
at the time of peak pressure from COVID-19 hospitalizations on
the United Kingdom health service, meant that we were limited
regarding the number of individuals receiving the short interval
schedule we could recruit. On the other hand, this rapid change
in policy gave us a unique opportunity to directly compare the
immunogenicity of the extended versus the standard dosing
interval.
The importance of immune memory and the multiple ways in
which the immune system after vaccination can prevent severe
disease, including the role of memory pools, and specific func-
tional properties of binding Abs and cellular responses must be
borne in mind to avoid excessive focus on point measures of
circulating NAb levels as a singular proxy for vaccine-induced
immunity. Our study demonstrates that two doses of
BNT162b2 are highly immunogenic for Abs and T cells across
the studied range of dosing intervals. When community levels
of circulating SARS-CoV-2 virus are low, the extended dosing in-
terval appears to be suitable for immunogenicity, but this needs
to be weighed against themore immediate benefits of two doses
over one. Policy decisions around vaccine dosing intervals will
depend on several factors, including the current prevalence of
SARS-CoV-2, which variants of concern are emerging, popula-
tion susceptibility, and vaccine supply. However, robust immu-
nologic data can now inform such policies.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Purified NA/LE mouse anti-human
CD28 (Clone: CD28.2)
BD Biosciences, UK Cat#555725; RRID:AB_396068
Purified NA/LE mouse anti-human
CD49d (Clone: 9F10)
BD Biosciences, UK Cat#555501; RRID:AB_2130052
BV510 mouse anti-human
CD3 (Clone: UCHT1)
BD Biosciences, UK Cat#563109: RRID:AB_2732053
Brilliant Violet 421 mouse anti-human
CD8 (Clone: RPA-T8)
BD Biosciences, UK Cat#562428; RRID:AB_11154035
PE mouse anti-human
TNFa (Clone: MAb11)
Thermo Fisher Scientific, Cat#12-7349-82; RRID:AB_466208
PERCP/ Cyanine 5.5 mouse
anti-human CD4 (Clone: RPA-T4)
Biologend, UK Cat#300530: RRID:AB_394493
APC-Cy7 mouse anti-human
CD14 (Clone: MfP9)
BD Biosciences, UK Cat#557831: RRID:AB_396889
FITC mouse anti-human
IFNg Clone: 45-15)
Miltenyi Biotec Ltd Cat#130-113-492; RRID:AB_2733589
APC mouse anti-human
IL-2 (5344.111)
BD Biosciences, UK Cat#341116; RRID:AB_400574
PE-Cy7 mouse anti-human CD107a
(Clone: H4A3)




Human anti-NP (mAb206) Dejnirattisai et al., 2021 N/A
Anti-Human IgG (Fc specific)-Peroxidase Sigma Cat#A0170; RRID:AB_257868
Bacterial and virus strains
SARS-CoV-2/P.1 Dejnirattisai et al., 2021 N/A
SARS-CoV-2/B.1.617.2 Wendy Barclay and
Thushan De Silva
N/A
SARS-CoV-2 (Australia/VIC01/2020) Caly et al., 2020 N/A
SARS-CoV-2/B.1.351 Public Health England N/A
Chemicals, peptides, and recombinant proteins
TrueBlue Peroxidase Substrate Insight Biotechnology Cat#5510-0030
Dulbecco’s Modified Eagle Medium, high
glucose
Sigma-Aldrich Cat#D5796
Custom synthesized peptides (18-mers) Mimotopes http://www.mimotopes.com
Dimethyl Sulfoxide Sigma Cat#D2650-100ML





Fetal Bovine Serum Sigma Cat#F9665-500ML




GlutaMAX Supplement GIBCO Cat#35050061
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Phosphate buffered saline tablets Fisher Scientific Cat#12821680
Fetal Bovine Serum GIBCO Cat#12676029
Carbonate/bicarbonate capsules Sigma Aldrich Cat#C3041-100CAP
ProMix CEF peptide pool Proimmune, Oxford Cat#PX-CEF
Phytohemagglutinin-L Sigma Aldrich Cat#11249738001
Carboxymethyl cellulose Sigma Cat#C4888
Tween 20 Sigma Aldrich Cat#P2287-500ml
1-Step NBT/BCIP Substrate Solution Life Technologies Cat#34042
LIVE/DEAD fixable near-IR dead cell
stain kit
Thermo Fisher Scientific Cat#L34975
Perm/Wash Buffer (10x) BD Biosciences Cat#554723
Brefeldin A Merck, UK Cat#B6542
PMA Merck, UK Cat#P1585
Ionomycin calcium salt from
Streptomyces conglobatus
Merck, UK Cat#I0634
DPBS, no calcium, no magnesium Thermo Fisher Scientific Cat#14190144
37% Formaldehyde solution Merck, UK Cat#F8775
GIBCO Fetal Bovine Serum,
qualified, heat inactivated
Thermo Fisher Scientific, UK Cat#10500064




Bovine Serum Albumin (BSA) Merck, UK Cat#A9418
Critical commercial assays
V-PLEX COVID-19 Coronavirus









Human IgA/IgG FluoroSpotFLEX kit Mabtech Cat#X-06G05R-10
Human memory B cell stimpack Mabtech Cat#3660-1
Human IFNg ELISpot Basic kit Mabtech Cat#3420-2A
Deposited data
Immunogenicity of standard and extended
dosing intervals of BNT162b2 mRNA
vaccine. Payne et al.
Mendeley Data https://doi.org/10.17632/fyp26zjgmj.1
Experimental models: Cell lines
Vero cells ATCC Cat#CCL-81
Software and algorithms
Discovery Bench 4.0 Meso Scale Discovery,
Rockville, MD, USA
Immunoassay Analysis Software | Meso
Scale Discovery
Prism 8.0 GraphPad https://www.graphpad.com/
scientific-software/prism/
IBM SPSS Software 26 IBM https://www.ibm.com/us-en/?ar=1
AID ELISpot software 8.0 Autoimmun Diagnostika http://www.elispot.com/products/software
Flojo 10.7.1 BD Biosciences https://www.flowjo.com/
R version 4.0.4 (2021-02-15)–‘‘Lost
Library Book’’
Web-based open source software https://www.r-project.org
R studio version 1.1.463 Web-based open source software https://www.rstudio.com
Other
FacsCanto II cytometer BD Biosciences UK N/A
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d Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul
Klenerman (paul.klenerman@ndm.ox.ac.uk).
Materials availability
d This study did not generate new unique reagents.
Data and code availability
d IFN ELISpot data, MSDdata, ACE2 inhibition data, neutralizing antibody data and intracellular cytokine assay data derived from
human samples have been deposited atMendeley Data and are publicly available as of the date of publication. The DOI is listed
in the key resources table.
d De-identified participant metadata have been deposited with the aboveMendeley data and are publicly available as of the date
of publication.
d This paper does not report original code.
d Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Primary Cell cultures
Vero cells (ATCC CCL-81) were cultured in Dulbecco’s Modified Eagle Medium, high glucose (Sigma-Aldrich), supplemented with
10% (v/v) heat-inactivated fetal bovine serum (GIBCO), 100 units/ml penicillin, 100 mg/ml streptomycin, 2mM L-Glutamine (Sigma)
and 2mM GlutaMax (GIBCO).
Viral Stocks
Live virus experiments were conducted in containment level 3 facilities in line with UK’s Advisory Committee on Dangerous Patho-
gens (ACDP) guidelines. SARS-CoV-2/human/AUS/VIC01/2020 (Caly et al., 2020), SARS-CoV-2/B.1.1.7 and SARS-CoV-2/B.1.351
were provided by Public Health England, P.1 from a throat swab from Brazil were grown in Vero (ATCC CCL-81) cells. Cells were
infected with the SARS-CoV-2 virus using an MOI of 0.0001. Virus containing supernatant was harvested at 80% cytopathic effect,
and spun at 3000 rpm at 4C before storage at 80C. Viral titers were determined by a focus-forming assay on Vero cells. Victoria
passage 5, B.1.1.7 passage 2, B.1.351 passage 4 and P.1 passage 1 stocks were sequenced to verify that they contained the ex-
pected spike protein sequence and no changes to the furin cleavage sites. The B.1.617.2 virus was kindly provided Wendy Barclay
and Thushan De Silva and contained the following mutations compared to the Wuhan sequence: T19R, G142D, D156-157/R158G,
A222V, L452R, T478K, D614G, P681R, D950N.
Human participants
The PITCH study
Healthcare workers (HCWs) were recruited to the PITCH study Consortium Study at National Health Service (NHS) hospitals in five
centers in England (University Hospitals Birmingham NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Sheffield Teaching
Hospitals NHS Foundation Trust). Participants were recruited both with and without a history of SARS-CoV-2 infection. Individuals
were defined as SARS-CoV-2 naive or previously infected based on documented PCR and/or serology results from local NHS trusts,
or the MSD assay S and N antibody results if these data were not available locally. All participants received the BNT162b2 Pfizer/
BioNTech vaccine. The vaccine dosing interval was either a ‘‘short’’ 3-5 week interval (median 24 days, IQR 21-27, range 14-35),
or a ‘‘long’’ 6-14 week interval (median 71 days, IQR 64-77, range 45-105). The immune response data from baseline and 4 weeks
after the first dose has been previously reported, alongside data for 21 HCWs 4 weeks after the second vaccine in a short dosing
regimen (Angyal et al., 2021). PITCH is a sub-study of the SIREN study which was approved by the Berkshire Research Ethics Com-
mittee, Health Research 250 Authority (IRAS ID 284460, REC reference 20/SC/0230), with PITCH recognized as a sub-study on 2
December 2020. SIREN is registered with ISRCTN (Trial ID:252 ISRCTN11041050). Some participants were recruited under aligned
study protocols. In Birmingham participants were recruited under the Determining the immune response to SARS-CoV-2 infection in
convalescent health care workers (COCO) study (IRAS ID: 282525). In Liverpool some participants were recruited under the ‘‘Human
immune responses to acute virus infections’’ Study (16/NW/0170), approved by North West - Liverpool Central Research Ethics
Committee on 8March 2016, and amended on 14th September 2020 and 4thMay 2021. In Oxford, participants were recruited under
theGI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & TheHumber - Sheffield Research
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Ethics Committee on 29 July 2016, which has been amended for this purpose on 8 June 2020. In Sheffield, participants were recruited
under the Observational Biobanking study STHObs (18/YH/0441), which was amended for this study on 10 September 2020. The
study was conducted in compliance with all relevant ethical regulations for work with human participants, and according to the prin-
ciples of the Declaration of Helsinki (2008) and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP)
guidelines. 589 participants were recruited in PITCH study; Female:Male ratio 74:26, Median age 43 (range 21-71). Further demo-
graphics are reported in Table 1. Written informed consent was obtained for all participants enrolled in the study.
The SIREN Study
The SIREN study is a separate ongoing study with themethodology published previously (Hall et al., 2021). SIREN is a large prospec-
tive cohort study of healthcare workers and allied staff aged 18 years and above working in UK National Health Service (publicly
funded) hospitals. The vaccine effectiveness analysis included in Figure 1A of this paper presents a repeat analysis after an extended
follow-up period (up to 12 March 2021) to that previously published (Angyal et al., 2021); data up to 5 February 2021. In brief, effec-
tiveness of the BNT162b2 vaccine against PCR-confirmed infection (asymptomatic and symptomatic) was estimated in SIREN
participants followed up from 7 December 2020 to 12 March 2012, by comparing time to infection in vaccinated and unvaccinated
participants. Participants underwent fortnightly asymptomatic SARS-CoV-2 PCR testing and monthly antibody testing, and all tests
(including symptomatic testing) outside SIREN were captured. Baseline risk factors were collected at enrolment, symptom status
was collected every 2 weeks, and vaccination status was collected through linkage to the National Immunisations Management
System and questionnaires. Historic SARS-CoV-2 PCR and antibody testing data was used to determine each participants prior
SARS-CoV-2 infection status (positive or negative cohort) at the beginning of the analysis period (7 December 2020). Vaccine effec-
tiveness of the BNT162b2 vaccine was calculated using a piecewise exponential hazard mixed-effects model (shared frailty-type
model) using a Poisson distribution, which adjusted for the variable incidence during the follow-up period and important confounders.
The study is registered with ISRCTN, number ISRCTN11041050, and is ongoing. 25,661 participants were included in this analysis,
Female:Male ratio 84:16.
METHOD DETAILS
Study design and sample collection
In this prospective, observational, cohort study, HCWs were recruited into the PITCH study from across the five centers. Individuals
consenting to participate were recruited by word of mouth, hospital e-mail communications and from hospital-based staff screening
programmes for SARS-CoV-2, including HCWs enrolled in the national SIREN study at three sites (Liverpool, Newcastle and Shef-
field). Eligible participants were adults aged 18 or over currently working as an HCW, including allied support and laboratory staff, and
were sampled for the current study between 4 December 2020 and 27 May 2021. Participants on the ‘‘long’’ dosing interval received
phlebotomy for assessment of immune responses prior to first dose of vaccine (median 23 days, IQR 6/55), 4 weeks after the first
dose (median 28 days, IQR 26/31), 8 weeks after the first dose (median 70 days, IQR 62/75), 4 weeks after the second dose (median
28 days, IQR 25/32) and 13 weeks after the second dose (median 94 days, IQR 91/103). Participants on the ‘‘short’’ dosing interval
received phlebotomy for assessment of immune responses 1 week after the second dose (median 7 days, IQR 7/8,) 4 weeks after the
second dose (median 28 days, IQR 27/33) and 13 weeks after the second dose (median 98 days, IQR 93/122). An overview of assays
performed is detailed in Table S1. Clinical information including BNT162b2 immunisation dates, date of any prior SARS-CoV-2 infec-
tion defined by a positive PCR test and/or detection of antibodies to spike or nucleocapsid protein, presence or absence of symp-
toms, time between symptom onset and sampling, age, gender and ethnicity of participant was recorded.
Focus Reduction Neutralization Assay (FRNT)
The neutralization potential of antibodies (Ab) was measured using a Focus Reduction Neutralization Test (FRNT), where the reduc-
tion in the number of the infected foci is compared to a negative control well without antibody. Briefly, serially diluted Ab or plasma
was mixed with SARS-CoV-2 strain Victoria or P.1 and incubated for 1 hr at 37C. The mixtures were then transferred to 96-well, cell
culture-treated, flat-bottom microplates containing confluent Vero cell monolayers in duplicate and incubated for a further 2 hr fol-
lowed by the addition of 1.5% semi-solid carboxymethyl cellulose (Sigma) overlaymedium to eachwell to limit virus diffusion. A focus
forming assay was then performed by staining Vero cells with human anti-nucleocapsid monoclonal Ab (mAb206) followed by perox-
idase-conjugated goat anti-human IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per well in the absence of
antibodies, were visualized by adding TrueBlue Peroxidase Substrate (Insight Biotechnology). Virus-infected cell foci were counted
on the classic AID ELISpot reader using AID ELISpot software. The percentage of focus reduction was calculated and IC50was deter-
mined using the probit program from the SPSS package.
Mesoscale Discovery (MSD) binding assays
IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and seasonal coronaviruses were measured using a multiplexed MSD
immunoassay: The V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit from Meso Scale Diagnostics, Rockville, MD USA. A MULTI-
SPOT 96-well, 10 spot plate was coated with three SARS CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike trimers,
as well as spike proteins from seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63, and bovine
serum albumin. Antigens were spotted at 200400 mg/mL (MSD Coronavirus Plate 3). Multiplex MSD assays were performed as
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per the instructions of themanufacturer. Tomeasure IgG antibodies, 96-well plates were blockedwithMSDBlocker A for 30minutes.
Following washing with washing buffer, samples diluted 1:1,000-10,000 in diluent buffer, or MSD standard or undiluted internal MSD
controls, were added to the wells. After 2-hour incubation and a washing step, detection antibody (MSD SULFO-TAG Anti-Human
IgG Antibody, 1/200) was added. Following washing, MSD GOLD Read Buffer B was added and plates were read using a MESO
SECTOR S 600 Reader. The standard curve was established by fitting the signals from the standard using a 4-parameter logistic
model. Concentrations of samples were determined from the electrochemiluminescence signals by back-fitting to the standard curve
and multiplied by the dilution factor. Concentrations are expressed in Arbitrary Units/ml (AU/ml). Cut-offs were determined for each
SARS-CoV-2 antigen (S, RBD and N) based on the concentrations measured in 103 pre-pandemic sera + 3 Standard Deviation. Cut-
off for S: 1160 AU/ml; cut-off for RBD: 1169 AU/ml; cut-off for N: 3874 AU/ml.
MSD ACE2 inhibition assay
The V-PLEX SARS-CoV-2 Panel 7 (ACE2) Kit, fromMSD, Rockville, MD, amultiplexedMSD immunoassay, was also used tomeasure
the ability of human sera to inhibit ACE2 binding to SARS-CoV-2 spike (B, B.1, B.1.1.7, B.1.351 or P.1). A MULTI-SPOT 96-well, 10
spot plate was coated with five SARS-CoV-2 spike antigens (B, B.1, B.1.1.7, B.1.351 or P.1). Multiplex MSD Assays were performed
as permanufacturer’s instructions. Tomeasure ACE2 inhibition, 96-well plates were blockedwithMSDBlocker for 30minutes. Plates
were then washed in MSD washing buffer, and samples were diluted 1:10 – 1:100 in diluent buffer. Importantly, an ACE2 calibration
curve which consists of a monoclonal antibody with equivalent activity against spike variants was used to interpolate results as arbi-
trary units (units/ml), with 1 unit being equivalent to 1ug/ml neutralising activity of the standard. Furthermore, internal controls and the
WHO SARS-CoV-2 Immunoglobulin international standard (20/136) were added to each plate. After 1-hour incubation recombinant
human ACE2-SULFO-TAG was added to all wells. After a further 1-hour plates were washed and MSD GOLD Read Buffer B was
added, plates were then immediately read using a MESO SECTOR S 600 Reader.
Memory B cell Fluorospot assay
Cryopreserved PBMCs were thawed and cultured for 72 hours with polyclonal stimulation containing 1mg/ml R848 and 10ng/ml IL-2
from the Human memory B cell stimpack (Mabtech). Using the Human IgA/IgG FluoroSpotFLEX kit (Mabtech), stimulated PBMCs
were then added at 2x105 cells/well to fluorospot plates coated with 10mg/ml Sars-CoV-2 spike glycoprotein diluted in PBS. Plates
were incubated for 16 hours at 37C and developed according to themanufacturer’s instructions (Mabtech). Analysis was carried out
with AID ELISpot software 8.0 (Autoimmun Diagnostika). All samples were tested in triplicates and response wasmeasured as spike-
specific spots per million PBMCs with PBS background subtracted.
T cell ELISpot assays
The PITCH ELISpot Standard Operating Procedure has been published previously (Angyal et al., 2021). Interferon-gamma (IFNg) ELI-
Spot assays were set up from cryopreserved PBMCs using the Human IFNg ELISpot Basic kit (Mabtech 3420-2A). A single protocol
was agreed across the centers as previously published (Angyal et al., 2021), and we found no significant difference in magnitude of
ELISpot response to spike 4 weeks after the second vaccine across the five centers (Figure S3B).
MultiScreen-IP filter plates (Millipore, MAIPS4510) were coated with 50ul per well using the ELISpot Basic kit capture antibody
(clone 1-D1K) at 10 mg/ml diluted in sterile phosphate buffered saline (PBS; Fisher Scientific) and sterile carbonate bicarbonate
(Sigma Aldrich) for 8 to 48 hours at 4C. PBMCs were thawed and rested for 3-6 hours in RPMI media (Sigma) supplemented
with 10% (v/v) Fetal Bovine Serum (Sigma), 1% (v/v) L-Glutamine (Sigma) and 1% (v/v) Penicillin/Streptomycin (Sigma) at 37C, prior
to stimulation with peptides. The capture antibody coated plates were washed four times with sterile PBS, then blocked with RPMI
media supplementedwith 10% (v/v) Fetal Bovine Serum and 1% (v/v) penicillin/streptomycin for two hours at 37C.Overlapping pep-
tide pools (18-mers with 10 amino acid overlap. Mimotopes) representing the spike (S), Membrane (M) or nucleocapsid (N) SARS-
CoV-2 proteins were added to 250,000 PBMCs/well at a final concentration of 2 mg/ml for 16 to18 hours. For selected individuals,
pools representing the S1 and S2 subunits of variant of concern were also included (B.1.35/beta and P.1/gamma). Pools consisting
of CMV, EBV and influenza peptides at a final concentration of 2mg/ml (CEF; Proimmune) and phytohemagglutinin-L (Sigma) were
used as positive controls. DMSO was used as the negative control at the equivalent concentration to the peptides. Wells were
then washed with PBS with 0.05% (v/v) Tween20 (Sigma Aldrich) and incubated with the ELISpot Basic kit biotinylated detection
antibody (clone 7-B6-1) diluted in PBSwith 0.05% (v/v) Tween20 at 1 mg/ml, for 2 hours at room temperature.Wells were thenwashed
with PBS with 0.05% (v/v) Tween20, and then incubated with the ELISpot Basic kit streptavidin-ALP, diluted in PBS at 1 mg/ml for 1.5
hours at RT. Wells were then washed with PBS and color development was carried out using the 1-step NBT/BCIP Substrate Solu-
tion. 50ul of filtered NBT/BCIP was added to each well for 15 minutes at RT. Color development was stopped by washing the wells
with tap water. Air dry plates were scanned and analyzed with the AID Classic ELISpot reader (software version 8.0, Autoimmune
Diagnostika GmbH, Germany). Antigen-specific responses were quantified by subtracting the mean spots of the control wells
from the test wells and the results were expressed as spot-forming units (SFU)/106 PBMCs.
Intracellular cytokine staining
T cell responses in selected IFNg ELISpot positive samples were characterized further using intracellular cytokine staining (ICS) after
stimulation with overlapping spike peptide pools. In brief, 1-1.5 3 106 cells were plated in RPMI media (Merck) supplemented
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with 10% (v/v) Fetal Bovine Serum (ThermoFisher), 1% (v/v) L-Glutamine (Sigma) and 1% (v/v) Penicillin/Streptomycin (Sigma) and
co-stimulatory antibodies; anti-CD28 (BD)and anti-CD49d (BD) in a 96 well U-bottom plate and peptide pools were added at 2 mg/ml
final concentration for each peptide. DMSO was used as the negative control at the equivalent concentration to the peptides. As a
positive control, cells were simultaneously stimulated with ionomycin (Sigma) at 500ng/ml and PMA (Sigma) at 50ng/ml final concen-
trations. Degranulation of T cells, a functional marker of cytotoxicity (Betts et al., 2003), was measured by the addition of an anti-
CD107a specific antibody (BD) at 1 in 20 dilution during the culture. The cells were then incubated at 37C, 5%CO2 for 1 hour before
adding 10ug/ml Brefeldin A (Merck). Samples were incubated at 37C, 5% CO2 for a further 5 hours before proceeding with staining
for flow cytometry.
First, stimulated cells were stained with live/dead stain (ThermoFisher) 1:500 at RT in the dark for 20minutes then washed in DPBS
(ThermoFisher) followed by spinning the samples at 300 g for 5 minutes. Cells were then fixed in 2% formaldehyde (Merck) for 20 mi-
nutes, then frozen at 80C in DPBS supplemented with 1% (v/v) bovine serum albumin (Merck), 10% (v/v) DMSO (Sigma). Cells
were then thawed in batches, centrifuged at 400 g for 5 minutes to remove the freezing mix before permeabilization in 1x Perm/
Wash buffer (BD) for 20-25 minutes at RT. Staining was performed in the dark at RT for 30 minutes in 1x Perm/Wash buffer with
the antibodies listed in Key resources table, then the cells were washed and resuspended in DPBS. The samples were run on a Facs-
Canto II cytometer and the data were analyzed using FlowJo software version 10 (Treestar). Gating strategy exemplified in Figure S4.
QUANTIFICATION AND STATISTICAL ANALYSIS
Continuous variables are displayed with median and interquartile range (IQR). Paired comparisons were performed using the Wil-
coxon matched pairs signed rank test. Unpaired comparisons across two groups were performed using the Mann-Whitney test.
Two-tailed P values are displayed. Statistical analyses were done using R version 3.5.1 and GraphPad Prism 9.0.1.
Statistical regression models
Multivariate regression models were created to estimate the associations between variables in the study cohort and antibody and
T cell immune response. Variables included age, sex, ethnicity, previous infection, time point and vaccine dosing interval. Interactions
and co-linearity between variables were explored and variables analyzed in separate models where necessary. Generalized linear
models were created to estimate associations between the variables sex (discrete), age (continuous), Ethnicity (discrete), previous
infection (discrete), and vaccine interval regimen (discrete) on spike ELISpot response (spike B SFU/106; log transformed) or spike
IgG response (SARS-Cov-2 S AU/ml; log transformed). Linear mixed-effect models were created to estimate associations between
variables sex (discrete), age (continuous), sample time point (discrete), previous infection (discrete) and Ethnicity (discrete). on spike
ELISpot response (spike B SFU/106; log transformed) or spike IgG response (SARS-Cov-2 S AU/ml; log transformed) in data from the
Long dosing interval. Interactions were found between previous infection and vaccine dosing interval in model 1 and 2 for Spike IgG
responses, so separate models were run for naive and previously infected individuals. GLM and LMER models were performed in R
/R studio. Summary tables were reported. To check assumptions were met, residuals versus fitted and Normal Q-Q diagnostic plots
were created.
Model 1 < - glm (immune responseage + sex + previous infection + vaccine dosing interval + previous infection: vaccine dosing
interval, data = data)
Model 2 < - glm (immune response age + sex + previous infection + vaccine dosing interval + ethnicity + previous infection:
vaccine dosing interval, data = data)
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Supplemental figures
Figure S1. Correlation of NAb titers with T cell and IgG responses and vaccine interval, related to Figures 2 and 3A
A. Relationship between IgG response to Spike (MSD) and neutralizing antibody (nAB) response to Victoria from all time points and vaccine dosing intervals . B.
Relationship between IgG response to Receptor binding domain (MSD) and nAB response to Victoria from all time points and vaccine dosing intervals. C.
Relationship between IgG response to spike (MSD) and nAB response to Victoria at dose-2 plus 4 weeks in short (3 weeks) and long (10 weeks) vaccine dosing
intervals. D. Relationship between IgG response to Receptor binding domain (MSD) and nAB response to Victoria at dose-2 plus 4weeks weeks in short (3 weeks)
and long (10 weeks) vaccine dosing intervals. E. Relationship between Nab to Victoria and T cell responses to Spike at dose-1 plus 4 weeks. F. Relationship
between Nab to Victoria and T cell responses to Spike at dose-1 plus 10 weeks. G. Relationship between Nab to Victoria and T cell responses to Spike at dose-2
plus 4 weeks weeks in short (3 weeks) and long (10 weeks) vaccine dosing intervals. H. Relationship between Nab to Victoria and T cell responses to Spike at
dose-2 plus 13 weeks in short (3 weeks) and long (10 weeks) vaccine dosing intervals I. Correlation between vaccine dosing interval and neutralizing antibodies at
2nd dose plus 4 weeks. Spearman’s correlation was performed. Grey symbols indicate naive participants.
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Figure S2. Effect of vaccine dosing interval and MSD sensitivity threshold on IgG responses, related to Figures 2B and 3C
A. Effect of a dosing interval grouped 4 weekly on SARS-CoV-2 S-specific IgG responses in naive (gray symbols) and pre-infected individuals (red symbols). IgG
responses were measured in serum 4weeks after the second dose using multiplexed MSD immunoassays and are shown in Arbitrary Units/ml (AU/ml). Bars
represent the median with interquartile range. Unpaired comparisons between the groups were performed using a Mann-Whitney test.
B. Effect of a short or a long vaccine dosing interval on SARS-CoV-2 S-, RBD- and N-specific IgG responses in naive (gray symbols) and pre-infected individuals
(red symbols) after removing participants with IgG N responses above the sensitivity threshold (3,874 AU/ml). IgG responses were measured in serum 4 weeks
following the second dose usingmultiplexedMSD immunoassays and are shown in Arbitrary Units/ml (AU/ml). Bars represent themedian with interquartile range.
Unpaired comparisons between the groups were performed using a Mann-Whitney test. Horizontal dotted lines represent the sensitivity threshold of each assay
based on pre-pandemic sera.
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Figure S3. Effect of ethnicity and study site on IgG and T cells responses and comparison of IgG responses with alphacoronavirses and
betacoronaviruses 4 weeks after the second dose of vaccine, related to Table 2 and Figure 3
A. Correlation of IFN-y ELISpot responses to Spike B and anti-spike IgG response, in participants 4 weeks after the second dose in naive, and previously infected
individuals who received either the long or short interval dose. Data points are colored by ethnic group. Spearman’s correlation was performed.
B. Comparison of of IFN-y ELISpot responses to Spike B, from cryo-preserved PBMCs 4 weeks after second dose in naive, and previously infected individuals
who received the long interval dose, across the 5 centers (BIR: Birmingham, LIV: Liverpool, NEW: Newcastle, OX: Oxford, SHEF: Sheffield). Data are shown as
spot-forming units per million peripheral blood mononuclear cells (SFU/106 PBMCs). Unpaired comparisons across two groups were performed using the Mann
Whitney test. Grey symbols represent naive individuals, Red symbols represent previously infected individuals.
C. Alpha coronavirus and beta coronavirus spike-specific IgG responses in naive (gray circles, n = 151) and pre-infected individuals (red circles, n = 169)
vaccinated with a long interval between the doses. IgG responses were measured in unpaired sera before vaccination (pre) and4 weeks after the second dose
(1-dose +4 wks) using multiplexed MSD immunoassays. Data are shown in Arbitrary Units/ml (AU/ml). Bars represent the median with interquartile range. Un-
paired comparisons between the groups were performed using a Mann-Whitney test. Fold change values each refer to the P value comparisons directly below.
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Figure S4. Representative gating strategy for ICS analysis, related to Figure 4
(A) Description of gates left-to-right showing sequential gates used in the initial analysis of each subject. Cell doublets were removed using forward scatter (FSC)
parameters. Lymphocytes were selected by FSC and side scatter (SSC), CD3 positive but non-Live-dead stained living populations were carried forward to
isolate CD4+ and CD8+ T Cells. (B) The gates used to define differences between different cytokine expression and (C) total individual cytokine expression in
CD4+ and (D,E) CD8+ respectively. DMSO and PMAI represent negative and positive control conditions to demonstrate the contrast in cytokine expression.
These were also used in setting the gate boundaries in each subject for the analysis of SARSCoV2 Spike protein responses.
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Figure S5. Effect of previous SARS-CoV-2 infection on magnitude of IgG and T cell responses, related to Figure 2
A-B. SARS-CoV-2 spike(S)-, receptor-binding domain (RBD)- and nucleocapsid(N)-specific IgG time course in naive (gray circles, n = 234) and pre-infected
individuals vaccinated (red circles, n = 228) with a long (A) or short (B) interval between the doses. IgG responses were measured in unpaired sera before
vaccination (pre), 4 weeks after the first dose (1-dose +4 wks), 8-12 weeks after 1st dose (1-dose + 10 wks), 4 weeks after the second dose (2-dose + 4wks), and
13 weeks after the second dose (2-dose +13 wks) using multiplexed MSD immunoassays. Data are shown in Arbitrary Units/ml (AU/ml). C. Comparison of IFN-y
ELISpot responses to Spike (Victoria) from cryo-preserved peripheral blood mononuclear cells (PBMCs) in 276 naive individuals and 165 previously-infected
individuals unmatched for pre-vaccine (pre), 4 weeks after 1st dose (1-dose +4 wks), 8-12 weeks after 1st dose (1-dose +10 wks) and 4 weeks after 2nd dose (2-
dose +4 wks). Data are shown as spot-forming units per million PBMCs (SFU/106 PBMCs). D. Impact of a short and a long vaccine dosing interval on the ability of
sera to inhibit ACE2 binding to SARS-CoV-2 spike (Victoria, B.1.1.7 (alpha), B.1.351 (beta) or P.1 (gamma)) 28 days after the second dose. ACE2 inhibition was
analyzed using a multiplexed MSD assay. Data are shown in units/ml. Naive, short: n = 23; Naive, long: n = 94; Pre inf, short: n = 14; Pre inf, long: n = 119.
Bars represent the median with interquartile range. Unaired comparisons between the groups were performed using a Mann-Whitney test. Fold change values
each refer to the P value comparisons directly below. Horizontal dotted lines represent the cut-offs of each assay based on pre-pandemic sera. Data from 51 of
the pre-vaccine, and 51 of the 1-dose +4 wks responses were previously published (Angyal et al., 2021).
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